Treatment of Reactive Arthritis with Biological Agents.
Anti-TNF
Biological therapy
Reactive arthritis
Spondyloarthritis
Journal
Current rheumatology reports
ISSN: 1534-6307
Titre abrégé: Curr Rheumatol Rep
Pays: United States
ID NLM: 100888970
Informations de publication
Date de publication:
23 Sep 2024
23 Sep 2024
Historique:
accepted:
04
09
2024
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
aheadofprint
Résumé
Reactive arthritis (ReA) is an inflammatory joint condition triggered by an infection elsewhere in the body, and this review aims to provide a comprehensive synthesis of recent studies including case reports and case series to determine whether biologics are a treatment option. Recent studies indicate that biological agents, including anti-TNF agents (infliximab, adalimumab, etanercept), anti-IL17 (secukinumab), and anti-IL6 (tocilizumab), are effective in treating refractory cases of ReA. Evidence suggests these agents are associated with significant clinical improvement. Notably, the data reveal that these biologics are generally well-tolerated, with a low incidence of major adverse events, which supports their safety profile for use in ReA. Biological agents, including anti-TNF, anti-IL17, and anti-IL6 therapies, can be safely and effectively used in the treatment of ReA when conventional therapies fail. It further emphasizes the need for a well-designed controlled trial to provide scientific basis for better informed clinical decisions in cases not responding to conventional treatment.
Identifiants
pubmed: 39312088
doi: 10.1007/s11926-024-01165-6
pii: 10.1007/s11926-024-01165-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Wu IB, Schwartz RA. Reiter’s syndrome: the classic triad and more. J Am Academy of Dermatol. 2008;59(1):113–21. https://doi.org/10.1016/j.jaad.2008.02.047 .
doi: 10.1016/j.jaad.2008.02.047
Fendler C, Laitko S, Sörensen H, Gripenberg-Lerche C, Groh A, Uksila J, Granfors K, Braun J, Sieper J. Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. Ann Rheum Dis. 2001;60(4):337–43. https://doi.org/10.1136/ard.60.4.337 .
doi: 10.1136/ard.60.4.337
pubmed: 11247862
pmcid: 1753604
Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014;13(4–5):546–9. https://doi.org/10.1016/j.autrev.2014.01.005 .
doi: 10.1016/j.autrev.2014.01.005
pubmed: 24418301
Rudwaleit MV, Van Der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–83. https://doi.org/10.1136/ard.2009.108233 .
doi: 10.1136/ard.2009.108233
pubmed: 19297344
Rudwaleit MV, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann rheum Dis. 2011;70(1):25–31. https://doi.org/10.1136/ard.2010.133645 .
doi: 10.1136/ard.2010.133645
pubmed: 21109520
Sieper J. Pathogenesis of reactive arthritis. Curr Rheumatol Rep. 2001;3(5):412–8. https://doi.org/10.1007/s11926-996-0012-8 .
doi: 10.1007/s11926-996-0012-8
pubmed: 11564373
Carter JD. Reactive arthritis: defined etiologies, emerging pathophysiology, and unresolved treatment. Infect Dis Clin. 2006;20(4):827–47. https://doi.org/10.1016/j.idc.2006.09.004 .
doi: 10.1016/j.idc.2006.09.004
Ngaruiya CM, Martin IB. A case of reactive arthritis: a great masquerader. Am J Emerg Med. 2012;31(1):266-e5. https://doi.org/10.1016/j.ajem.2012.04.019 .
doi: 10.1016/j.ajem.2012.04.019
Yin Z, Braun J, Neure L, Wu P, Liu L, Eggens U, Sieper J. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthr Rheum. 1997;40(10):1788–97. https://doi.org/10.1002/art.1780401010 .
doi: 10.1002/art.1780401010
Wendling D, Cedoz JP, Racadot E. Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol. 2009;28:187–90. https://doi.org/10.1007/s10067-008-1011-0 .
doi: 10.1007/s10067-008-1011-0
pubmed: 18827961
Meador R, Hsia E, Kitumnuaypong T, Schumacher HR. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin Exp Rheumatol. 2002;20(6; SUPP/28):S-130.
Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol. 2007;34(11):2285–90.
pubmed: 17937463
Holt I, Cooper RG, Hopkins SJ. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Investig. 1991;21(5):479–84. https://doi.org/10.1111/j.1365-2362.1991.tb01398.x .
doi: 10.1111/j.1365-2362.1991.tb01398.x
Chaurasia S, Shasany AK, Aggarwal A, Misra R. Recombinant Salmonella typhimurium outer membrane protein A is recognized by synovial fluid CD8 cells and stimulates synovial fluid mononuclear cells to produce interleukin (IL)-17/IL-23 in patients with reactive arthritis and undifferentiated spondyloarthropathy. Clin Exp Immunol. 2016;185(2):210–8. https://doi.org/10.1111/cei.12799 .
doi: 10.1111/cei.12799
pubmed: 27060348
pmcid: 4955008
Noto Llana M, Sarnacki SH, Aya Castañeda MD, Bernal MI, Giacomodonato MN, Cerquetti MC. Consumption of Lactobacillus casei fermented milk prevents Salmonella reactive arthritis by modulating IL-23/IL-17 expression. PLoS One. 2013;8(12):e82588. https://doi.org/10.1371/journal.pone.0082588 .
doi: 10.1371/journal.pone.0082588
pubmed: 24340048
pmcid: 3858332
Padhan P, Maikap D. Secukinumab therapy in reactive arthritis: Report of two cases. Modern Rheumatol Case Rep. 2022;6(1):22–4. https://doi.org/10.1093/mrcr/rxab014 .
doi: 10.1093/mrcr/rxab014
Gupta V, Mohta P, Sharma VK, Khanna N. A retrospective case series of 12 patients with chronic reactive arthritis with emphasis on treatment outcome with biologics. Indian J Dermatol Venereol Leprol. 2021;87(2):227–34. https://doi.org/10.4103/ijdvl.IJDVL_519_18 .
doi: 10.4103/ijdvl.IJDVL_519_18
pubmed: 31293276
Ahmed S, Padhan P. AB0632 Effectiveness of etanercept biosimilars in reactive arthritis: retrospective case control. Ann Rheum Dis. 2020;79:1611–2. https://doi.org/10.1136/annrheumdis-2020-eular.295 .
doi: 10.1136/annrheumdis-2020-eular.295
Van Mens LJ, van de Sande MG, Menegatti S, Chen S, Blijdorp IC, de Jong HM, Fluri IA, Latuhihin TE, van Kuijk AW, Rogge L, Yeremenko NG. Brief report: interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses. Arthr Rheumatol. 2018;70(12):1994–2002. https://doi.org/10.1002/art.40581 .
doi: 10.1002/art.40581
Brinster A, Guillot X, Prati C, Wendling D. Anti-TNF treatment of reactive arthritis. A monocentric experience. Joint Bone Spine. 2017;84(2):237–8. https://doi.org/10.1016/j.jbspin.2016.02.022 .
doi: 10.1016/j.jbspin.2016.02.022
pubmed: 27236263
Ahogo KC, Bataille M, Lasek A, Wantz M, Lebas D, Modiano P. A case of reactive arthritis (oculo-urethro-synovial syndrome) treated with infliximab. Ann Dermatol Venereo. 2017;144:804–5. https://doi.org/10.1016/j.annder.2017.08.004 .
doi: 10.1016/j.annder.2017.08.004
Edrees A. Successful use of etanercept for the treatment of Reiter’s syndrome: a case report and review of the literature. Rheumatol Int. 2012;32:1–3. https://doi.org/10.1007/s00296-011-2000-1 .
doi: 10.1007/s00296-011-2000-1
pubmed: 21785961
Gaylis NB. Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab. JCR: J Clin Rheumatol. 2012;18(3):153–4. https://doi.org/10.1097/RHU.0b013e31824e9151 .
doi: 10.1097/RHU.0b013e31824e9151
pubmed: 22426582
Meyer A, Chatelus E, Wendling D, Berthelot JM, Dernis E, Houvenagel E, Morel J, Richer O, Schaeverbeke T, Gottenberg JE, Sibilia J. Safety and efficacy of anti–tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis. Arthr Rheum. 2011;63(5):1274–80. https://doi.org/10.1002/art.30272 .
doi: 10.1002/art.30272
Schafranski MD. Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection. Rheumatology international. 2010;30(5):679–80. https://doi.org/10.1007/s00296-009-0965-9 .
doi: 10.1007/s00296-009-0965-9
pubmed: 19466419
Wechalekar MD, Rischmueller M, Whittle S, Burnet S. Hill CL 2010 Prolonged remission of chronic reactive arthritis treated with three infusions of infliximab. JCR: J Clin Rheumatol. 2010;16(2):79–80. https://doi.org/10.1097/RHU.0b013e3181d06f70 .
doi: 10.1097/RHU.0b013e3181d06f70
pubmed: 20216128
Tanaka T, Kuwahara Y, Shima Y, Hirano T, Kawai M, Ogawa M, Arimitsu J, Hagihara K, Narazaki M, Ogata A, Kawase I. Successful treatment of reactive arthritis with a humanized anti–interleukin-6 receptor antibody, tocilizumab. Arthr Care Res. 2009;61(12):1762–4. https://doi.org/10.1002/art.24899 .
doi: 10.1002/art.24899
Gill H, Majithia V. Successful use of infliximab in the treatment of Reiter’s syndrome: a case report and discussion. Clin Rheumatol. 2008;27:121–3. https://doi.org/10.1007/s10067-007-0692-0 .
doi: 10.1007/s10067-007-0692-0
pubmed: 17643185
Sánchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N. Use of adalimumab in poststreptococcal reactive arthritis. JCR: J Clin Rheumatol. 2007;13(3):176. https://doi.org/10.1097/RHU.0b013e3180690c1f .
doi: 10.1097/RHU.0b013e3180690c1f
pubmed: 17551391
Flagg SD, Meador R, Hsia E, Kitumnuaypong T, Schumacher HR Jr. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthr Care Res: Off J Am Coll Rheumatol. 2005;53(4):613–7. https://doi.org/10.1002/art.21323 .
doi: 10.1002/art.21323
Kaipiainen-Seppänen O, Niinisalo H, Korpilähde T, Virolainen J. Treatment of reactive arthritis with infliximab. Scandinavian J Rheumatol. 2003;32(2):122–4. https://doi.org/10.1080/03009740310000157 .
doi: 10.1080/03009740310000157
Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome. J Rheumatol. 2003;30(2):407–11.
pubmed: 12563704
Maikap D, Padhan P. Successful use of tofacitinib in reactive arthritis refractory to conventional therapies–a case series. Mod Rheumatol Case Rep. 2022;6(2):167–70.